Yes, one ISO 10993 evidence package can support multiple markets, but each market needs its own reviewer-facing explanation.
The strongest approach is to build one core biological-evaluation evidence base, then create market-specific summaries for FDA, EU MDR, and CDSCO that explain the same data in the language each pathway expects.
Teams often ask whether they can use the same ISO 10993 file for the United States, Europe, and India. The practical answer is that the same scientific evidence can often support all three, but the file should not look like a single document copied into three submissions. Reviewers are reading for different decision contexts.
What Can Usually Be Reused?
The strongest reusable layer is the factual evidence base: final device description, patient-contacting components, contact type and duration, material information, manufacturing and sterilization state, chemistry data, biological test reports, literature evidence, prior-device evidence, and toxicological risk assessment inputs.
If those inputs are complete and traceable, they can support FDA, EU MDR, and CDSCO-oriented files. If the inputs are weak, no amount of market-specific formatting will fix the core biological-safety argument.
Where the File Must Change
- FDA: the submission needs a clear, reviewable biocompatibility summary that connects device contact, endpoints, test data, waivers, chemistry, and TRA logic.
- EU MDR: the technical file must connect biological evaluation to Annex I GSPR logic, risk management, state of the art, and lifecycle controls.
- CDSCO: the same ISO 10993 evidence may be useful, but the India file often needs clearer framing around the Medical Devices Rules context, device classification, intended use, and submission/customer documentation.
The Risk of Copying the Same BER
A BER written for one market may be scientifically sound but commercially weak in another market. For example, an FDA summary may not show enough EU MDR GSPR traceability, while an EU MDR technical-file narrative may be too broad or indirect for a 510(k) reviewer trying to find endpoint conclusions quickly.
A Better Structure: One Evidence Base, Three Readouts
- Core evidence pack: device description, contact categorization, materials, chemistry, testing, literature, equivalence, and TRA.
- Master BEP/BER logic: endpoint-by-endpoint decision table with clear test, waiver, literature, chemistry, or TRA support.
- FDA readout: a concise endpoint and evidence summary suitable for the submission section or deficiency response.
- EU MDR readout: technical-file linkage to GSPR 10, risk management, clinical use, and lifecycle change control.
- CDSCO readout: India-ready documentation framing that explains the evidence in a way that supports local regulatory and customer review.
How to Decide What to Rewrite
Do not rewrite every section just because a new market is being added. First classify the content by function. Scientific evidence should remain stable unless the device, material, process, or interpretation has changed. Reviewer-facing explanation should be adapted to the decision-maker reading the file.
- Keep stable: factual device data, final test reports, chemistry outputs, material certificates, and documented processing or sterilization information.
- Adapt carefully: endpoint summary, waiver rationale, biological risk conclusion, GSPR mapping, FDA 510(k) summary language, and India-facing documentation notes.
- Rebuild only when needed: assumptions that no longer fit the current device, unsupported equivalence claims, weak chemistry interpretation, or old conclusions that do not match the target pathway.
What Should Stay Identical Across Markets
The scientific position should not contradict itself. If the same device, materials, processing, and evidence are being used, the biological safety conclusion should remain coherent across markets. What changes is the packaging of that conclusion: FDA may need a tight endpoint summary, EU MDR may need stronger technical-file traceability, and CDSCO or customer-facing files may need clearer device and evidence framing.
Reuse the evidence, not the exact wording. The best cross-market files preserve scientific consistency while changing the reviewer-facing explanation.
When to Run a Cross-Market Gap Review
A gap review is useful when a team already has a BEP, BER, TRA, or test package and wants to use it for another market. The review should check whether the evidence is complete, whether the endpoint conclusions are defensible, and whether each target pathway has the right summary format.
This is especially important for devices with chemistry-driven conclusions, implants, coatings, prolonged contact, material changes, or reviewer questions. In those cases, a small inconsistency in chemistry, TRA, or endpoint logic can create avoidable friction across multiple markets.
Official References
Before reusing the same ISO 10993 file, check whether the evidence and market readouts match.
Send the current BEP, BER, TRA, test summary, target markets, and submission timing. I can help identify what can be reused, what must be rewritten, and which gaps matter first.